Home › Companies › DYN

Dyne Therapeutics

Market cap $3.00B 187.4M shares (10-Q, Oct 30, 2026) × $16.02 close Nov 17, 2026

Most recent annual filing: 2026-03-02

Catalyst timeline

4 trackedQuarter catalyst calendar →
  1. DYNE-302 Ph1 readout2H 2026DYNE-302 Ph1 readout, 2H 2026, notable
  2. z-basivarsen pivotal topline1Q 2027z-basivarsen pivotal topline, 1Q 2027, material
  3. z-rostudirsen FDA decisionJan 21, 2027z-rostudirsen FDA decision, Jan 21, 2027, major
  4. Hercules covenant FDA approval~Oct 2027Hercules covenant FDA approval, ~Oct 2027, material

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (10 active programs)

Technology platforms

FORCE

TfR1-targeting Fab-conjugate delivery platform that links therapeutic payloads (PMOs, ASOs, siRNAs, enzymes) to a proprietary anti-TfR1 Fab via a clinically-validated linker, enabling targeted delivery to skeletal, cardiac and smooth muscle and CNS. Disease focus: neuromuscular diseases including DMD, DM1, FSHD, Pompe disease, rare skeletal muscle diseases, and cardiac/metabolic muscle diseases.

Targets: TfR1, transferrin receptor 1

Capital (as filed)

Cash
$913M cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments
$221M Sep 30, 2026
Operating cash flow
−$177M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$1.13B cash, runway into Q2 2028 per the update of Nov 5, 2026 — the company's own words as read there, not the filed figure

Offering documents (1)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (14)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (14 calls)

Every verdict Biotech Distilled has published on Dyne Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Buy core Dyne Therapeutics (DYN): Scientific Due Diligence for FORCE™ and Pipeline Products Dyne's FORCE platform has de-risked the biology of muscle delivery with undeniable dystrophin biomarker data, a fortress balance sheet, and platform optionality across DMD, DM1, FSHD, and Pompe, shifting the primary risk from efficacy to long-term safety and FDA regulatory posture.
  2. Buy core UPDATE: Dyne Secures Japan Orphan Drug Designation (ODD) Japan ODD for z-basivarsen completes a global regulatory trifecta, extending the DM1 exclusivity runway and reinforcing the thesis that the safety data package is passing muster with conservative global health authorities.
  3. Buy core UPDATE: Dyne Therapeutics (DYN) - Annual Audit Audited $1.1B cash position confirmed and T. Rowe Price's 26.6M share position signals high institutional conviction ahead of the BLA submission, with financial risk effectively minimized.
  4. Buy core UPDATE: Dyne Therapeutics (DYN) - Generational Moment 24-month cardiopulmonary preservation data in DMD solves the clinical meaningfulness question for the FDA, and Phase 3 HARMONIA initiation in DM1 with FDA-aligned protocol provides a clear path to full approval, dramatically de-risking the profile.
  5. Buy core UPDATE: Dyne Therapeutics (DYN) - The BLA is In On-time BLA submission with Priority Review requested confirms execution and keeps the Q1 2027 launch calendar intact; the de-risking already happened in March and the next inflection is the late-July filing acceptance.
  6. Buy core UPDATE: Dyne Therapeutics (DYN) - The Second Catalyst Lands ACHIEVE REC fully enrolled at n=71 with registrational dose locked at 6.8 mg/kg Q8W, giving DM1 hard timeline dates and confirming Dyne has hit every milestone on schedule, with DM1 representing a greenfield monopoly opportunity.
  7. Buy core UPDATE: Dyne Therapeutics (DYN) - The Non-Dilutive Top-Off Hercules facility expansion to $400M with $50M drawn and covenant pushed to July 2027 adds non-dilutive capital and removes the risk of a panic equity raise at the PDUFA window, widening the fortress balance sheet moat.
  8. Buy core UPDATE: Dyne Therapeutics (DYN) - The PDUFA Clock is Set FDA accepted the z-rostudirsen BLA with Priority Review and set a January 21, 2027 PDUFA, converting the regulatory overhang into a defined six-month window and validating the dystrophin surrogate as acceptable for accelerated approval consideration.
  9. Buy core UPDATE: Dyne Therapeutics (DYN) - The Day-After Raise The $300M equity raise the day after PDUFA acceptance is deliberate launch-prep capital that extends runway to Q2 2028 and funds commercial infrastructure, bending but not breaking the fortress balance sheet thesis despite ~8% dilution.
  10. Buy core UPDATE: Dyne Therapeutics (DYN) - The Raise Prices Offering priced at $20.50 with a wider-than-expected 12.6% discount and upsized to $375M, signaling the marginal institutional buyer needed a real concession, but the deal cleared and the FORZETTO RFF endpoint architecture confirms the AA-to-traditional-approval conversion pathway.
  11. Buy core UPDATE: Dyne Therapeutics (DYN) - The Third Package FDA IND clearance for DYNE-302 in FSHD activates the preclinical call option with a first-in-human siRNA payload on the FORCE platform, expanding the franchise claim and improving the downside shape if January delivers a CRL.
  12. Buy core UPDATE: Dyne Therapeutics (DYN) - The Q2 Print and Two Buried Footnotes Q2 burn of $178.6M reflects deliberate launch-prep spending, but a BIOSECURE designation on a Dyne CDMO and a Hercules revenue covenant starting nine months post-approval are new watch items that add supply chain and commercial execution risk without breaking the thesis.
  13. Buy core UPDATE: Dyne Therapeutics (DYN) - The One-Year DM1 Receipts Pooled 12-month ACHIEVE data show consistent myotonia, strength, function, and PRO improvements with clean safety across 143+ patient-years, supporting the DM1 greenfield thesis, while the 35% stock drawdown from the last post has no Dyne-specific clinical explanation.
  14. Buy core UPDATE: Dyne Therapeutics (DYN) - Q3 Print: The Flag on the Loading Dock Gets Lowered BIOSECURE designation on a Dyne CDMO is temporarily blocked by court injunction, Q3 burn held steady at ~$180M, and the January 21 PDUFA is unchanged, though a Novartis exon-44 competitor under priority review slightly weakens the franchise copy-paste story.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (8 quotes from 5 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (38)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 11, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

14 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)